SHORT COMMUNICATION
Modulation of matrix metalloproteinases MMP-2 and MMP-9 activity by hydrofiber-foam hybrid dressing – relevant support in the treatment of chronic wounds
Submission date: 2015-04-21
Acceptance date: 2015-05-26
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):391-394
KEYWORDS
ABSTRACT
Success in chronic wound therapy requires careful selection of appropriate dressing, which enables effective management of wound exudate. According to current knowledge, exudate may contain large quantities of proteases, including matrix metalloproteinases, MMP-2 and MMP-9, which are responsible for delay in wound healing. Therefore, neutralization of MMPs may be beneficial for treatment efficacy. The aim of the study was to test whether AQUACEL Foam, a novel, technologically advanced hydrofiber-foam hybrid dressing (HFHD), may interfere with proteolytic activity of MMPs in vitro.
The assessment included in vitro tests of liquid retention and measurement of human recombinant MMP-2 and MMP-9 activity. The MMPs activity was measured before and after their interaction with HFHD, using a fluorescent gelatinase assay kit and Real-Time PCR device. The in vitro tests have shown that the hydrofiber layer of HFHD revealed significant potential to decrease the activity of MMPs in the experimental system. The mentioned modulatory properties of AQUACEL Foam may contribute to a composed mechanism of its beneficial action. Furthermore, our finding may explain clinical effectiveness of HFHD observed in clinical settings.
The assessment included in vitro tests of liquid retention and measurement of human recombinant MMP-2 and MMP-9 activity. The MMPs activity was measured before and after their interaction with HFHD, using a fluorescent gelatinase assay kit and Real-Time PCR device. The in vitro tests have shown that the hydrofiber layer of HFHD revealed significant potential to decrease the activity of MMPs in the experimental system. The mentioned modulatory properties of AQUACEL Foam may contribute to a composed mechanism of its beneficial action. Furthermore, our finding may explain clinical effectiveness of HFHD observed in clinical settings.
REFERENCES (22)
1.
Mekkes JR, Loots MA, Van Der Wal AC, Bos JD (2003): Causes, investigation and treatment of leg ulceration. Br J Dermatol 148: 388-401.
2.
Bradbury AW (2010): Epidemiology and aetiology of C4-6 disease. Phlebology 25 Suppl 1: 2-8.
3.
Leaper DJ, Schultz G, Carville K, et al. (2012): Extending the TIME concept: what have we learned in the past 10 years? Int Wound J 9 Suppl 2: 1-19.
4.
Okan D, Woo K, Ayello EA, Sibbald G (2007): The role of moisture balance in wound healing. Adv Skin Wound Care 20: 39-53.
5.
Stanley AC, Park HY, Phillips TJ, et al. (1997): Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg 26: 994-1001.
6.
O’Toole EA, Marinkovich MP, Hoeffler WK, et al. (1997): Laminin-5 inhibits human keratinocytes migration. Exp Cell Res 233: 330-339.
7.
Waring MJ, Parsons D (2001): Physico-chemical characterisation of carboxymethylated spun cellulose fibres. Biomaterials 22: 903-912.
8.
Blome-Eberwein S, Johnson RM, Miller SF, et al. (2010): Hydrofiber dressing with silver for the management of split-thickness donor sites: a randomized evaluation of two protocols of care. Burns 36: 665-672.
9.
Walker M, Hobot JA, Newman GR, Bowler PG (2003): Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL®) and alginate dressings. Biomaterials 24: 883-890.
10.
Sprague AH, Khalil RA (2009): Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78: 539-552.
11.
Gill SE, Parks WC (2008): Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 40: 1334-1347.
12.
Basu R, Lee J, Morton JS, et al. (2013): TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension. Cardiovasc Res 98: 360-371.
13.
Schultz GS, Sibbald RG, Falanga V, et al. (2003): Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 11 Suppl 1: S1-S28.
14.
Serra R, Buffone G, Falcone D, et al. (2013): Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen 21: 395-401.
15.
Grzela T, Niderla-Bielinska J, Litwiniuk M, White R. (2014): The direct inhibition of MMP-2 and MMP-9 by an enzyme alginogel: a possible mechanism of healing support for venous leg ulcers. J Wound Care 23: 278-285.
16.
Parish LC, Dryjski M, Cadden S; Versiva XC Pressure Ulcer Study Group (2008): Prospective clinical study of a new adhesive gelling foam dressing in pressure ulcers. Int Wound J 5: 60-67.
17.
Philbin S (2013): Pressure ulcer management using sodium carboxymethylcellulose hydrofiber® foam dressings. Ostomy Wound Manage 59: 10-12.
18.
Amato B, Coretti G, Compagna R, et al. (2013): Role of matrix metalloproteinases in non-healing venous ulcers. Int Wound J [Epub ahead of print].
19.
Ladwig GP, Robson MC, Liu R, et al. (2002): Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 10: 26-37.
20.
Litwiniuk M, Bikowska B, Niderla-Bielińska J, et al. (2012): Potential role of metalloproteinase inhibitors from radiation-sterilized amnion dressings in the healing of venous leg ulcers. Mol Med Rep 6: 723-728.
21.
Rayment EA, Upton Z, Shooter GK (2008): Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 158: 951-961.
22.
Wiegand C, White RJ (2013): Binding and inhibition of protease enzymes, including MMPs, by a superabsorbent dressing in vitro. J Wound Care 22: 221-227.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
